Community Articles
via Decrypt · By Decrypt Editorial
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
DE
Decrypt Editorial(04:54 PM UTC)
1 min read
In brief
- Moderna (MRNA) jumped ~131% Wednesday after the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda hit its RFS and DMFS endpoints in resected melanoma.
- Intismeran autogene is a personalized mRNA neoantigen therapy built from each patient's tumor mutations, paired with Merck's Keytruda immunotherapy.
- Traders shorting Moderna faced ~$4.8B in mark-to-market losses as the stock…
Add COINOTAG as a Preferred Source
Add COINOTAG to your preferred sources in Google News and Search to see our coverage first.
Add on GoogleComments
Comments
Other Community Articles